J33

6,7-bis(chloranyl)-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one

Find entries where: J33

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	6,7-bis(chloranyl)-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
Identifiers	6,7-bis(chloranyl)-3,5-dihydro-1~{H}-imidazo[2,1-b]quinazolin-2-one
Formula	C₁₀ H₇ Cl₂ N₃ O
Molecular Weight	256.088
Type	NON-POLYMER
Isomeric SMILES	c1cc(c(c2c1N=C3NC(=O)CN3C2)Cl)Cl
InChI	InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
InChIKey	OTBXOEAOVRKTNQ-UHFFFAOYSA-N

Chemical Details
Formal Charge	0
Atom Count	23
Chiral Atom Count	0
Bond Count	25
Aromatic Bond Count	6

Drug Info: DrugBank

DrugBank ID	DB00261
Name	Anagrelide
Groups	approved
Description	Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]
Synonyms	Anagrelide Anagrelida Anagrelide hydrochloride monohydrate Anagrelide hydrochloride Anagrelidum
Brand Names	Anagrelide Anagrelide Mylan Agrylin PMS-anagrelide Mylan-anagrelide Sandoz Anagrelide Anagrelide Hydrochloride Dom-anagrelide Xagrid PHL-anagrelide
Indication	Anagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis. It is also beneficial in the amelioration of thrombocythemia symptoms including thrombo-hemorrhagic events.[L14153]
Categories	Agents producing tachycardia Antineoplastic Agents Antineoplastic and Immunomodulating Agents Antiplatelet agents Cardiovascular Agents Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 CYP1A2 Inhibitors (weak) Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Decreased Platelet Production Hematologic Agents Heterocyclic Compounds, Fused-Ring Highest Risk QTc-Prolonging Agents Narrow Therapeutic Index Drugs Phosphodiesterase 3 Inhibitors Phosphodiesterase Inhibitors Platelet-reducing Agents QTc Prolonging Agents Thrombocytosis
ATC-Code	L01XX35
CAS number	68475-42-3

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDL...	unknown	inhibitor
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	substrate,inhibitor

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682